Cannabis
Cannabis (Cannabis sativa) is one of the most commonly used complementary substances among cancer patients, with usage rates of 25–40% across studies. Patients use it in multiple forms for nausea, pain, anxiety, sleep, and appetite stimulation; a subset use it with curative intent. There is substantial evidence for oral cannabinoids (dronabinol, nabilone) for chemotherapy-induced nausea and vomiting when standard antiemetics fail — two are FDA-approved. Evidence for pain, appetite, and sleep is more limited. There is no clinical evidence supporting antitumor efficacy in humans; the 2024 ASCO guideline recommends against using cannabis to treat cancer.
Clinical Alerts
Drug Interactions
Immunotherapy Safety Signal EVIDENCE UNSETTLED
Emerging data suggest THC may reduce checkpoint inhibitor effectiveness. Mechanistic evidence: THC suppresses antitumor immunity via JAK/STAT inhibition in T cells through CNR2. Clinical evidence limited to small observational studies with methodological concerns. ASCO guideline notes this signal. Guidance may change.
Surgical Considerations
Higher risk for anesthesia complications. Patients should disclose type, form, dose, and frequency of use to their surgeon and anesthesia team.
Route-Specific Risks
Smoked cannabis: pulmonary risks. Unregulated products may contain pesticides, heavy metals, or synthetic cannabinoids. Edible dosing is highly variable and difficult to titrate.
Patient Information Environment
Where cannabis sits on the CAM continuum: Cannabis occupies a uniquely complex position. It is simultaneously a legitimate palliative tool with FDA-approved derivatives, a widely used complementary substance with an incomplete evidence base, and the subject of pervasive cure-narrative misinformation. A single patient conversation about cannabis may involve all three of these layers. Studies consistently show that 50% or more of cancer patients who use cannabis do not disclose this to their oncology team. Younger patients (20–39) are significantly less likely to disclose and more likely to feel uncomfortable with the conversation.
Misinformation environment: Cannabis-as-cure is the single largest category of alternative cancer treatment content on social media, representing 23.5% of all such content. The top false news story claiming cannabis cures cancer generated 4.26 million social media engagements; the top accurate story debunking this claim generated only 36,000 — a ratio of roughly 120:1. Online search interest in cannabis is growing at 10 times the rate of searches for standard cancer therapies, with higher volume in states where cannabis is legal. Nearly 1 in 4 cancer patients who use cannabis report doing so with the intent of treating their cancer.
What patients are encountering online:
- "Rick Simpson Oil" (RSO) cure narratives and testimonials
- Preclinical studies presented without context as evidence of human efficacy
- Claims of pharmaceutical/government suppression of cannabis cure data
- Conflation of symptom management evidence with anti-tumor claims
- Influencer testimonials with high production value and emotional resonance
- Dispensary marketing implying therapeutic benefits beyond evidence
How did the patient raise this?
Select the appropriate scenario.
Symptom Management
"My friend used CBD oil for pain during chemo — is that something I could try?"
Curative Intent, Still in Treatment
"My sister sent me this article about RSO — have you seen the studies?"
Stopped or Replacing Treatment
"I stopped my treatment last month — I'm doing RSO now."
Scenario A: Communication Guidance
Your task
The patient is seeking guidance on symptom management. This is a collaborative conversation.
What to watch for
Framing cannabis as something that requires your approval can discourage future disclosure — and studies consistently show that over 50% of cancer patients who use cannabis never tell their oncology team. Patients who feel judged for raising the topic stop raising it.
Opening the conversation
Start by asking, not telling. Find out what they've tried, where they heard about it, and what they're hoping it will do — this also reveals whether a Scenario B conversation is developing underneath.
Key strategies
Be specific, not vague: Research shows detailed information outperforms general guidance. Share what evidence supports (oral cannabinoids for CINV after standard antiemetics fail; modest neuropathic pain data) and where it's limited (appetite, sleep — patient-reported benefit but thin trial data).
Check interactions: Review current medications — especially taxanes, immunotherapy, anticoagulants. Name the specific drugs in their regimen affected by CYP450 inhibition.
Orient toward reliable sources: Name what makes online cannabis-cancer content unreliable: testimonials as evidence, preclinical results without context, dispensary marketing as medical guidance. Point to NCI, ACS, ASCO patient resources.
Document and normalize: Record use in the chart (type, form, dose, frequency, purpose). "I'm adding this the same way I would any supplement, so your whole team is on the same page."
⚑ If on immunotherapy: "There's something specific to your treatment I want to flag. Early signals suggest THC may reduce the T-cell activity your immunotherapy is designed to activate. The research isn't conclusive yet, but I want you to have that information so we can make a plan together."
Scenario B: Communication Guidance
Your task
The patient is still engaged with their treatment and still talking to you. The goal of this conversation is not to correct their information — it's to ensure they continue bringing you information in future visits.
What to watch for
Research shows that immediately correcting a patient's misinformation before understanding their reasoning reduces engagement and makes the patient less likely to raise concerns in future visits. The conversation that feels most clinically urgent — "I need to set them straight" — is the one most likely to close the door.
Opening the conversation
Before correcting, find out what the patient believes, where it came from, and why they find it compelling. Research on motivated reasoning shows that resistance to scientific information is rarely about not having the facts — it's driven by underlying fears, identity, worldviews, or distrust. A correction that ignores the underlying motivation will fail.
Key strategies
Identify what's driving the interest: If the patient is frightened, address the fear before the misinformation — the cannabis interest is a symptom, not the problem. If frustrated with side effects, redirect to the legitimate palliative evidence, giving them something real while moving them off the cure narrative. If influenced by a trusted person or community, don't compete with that relationship — align with it: "The people in your life want to help you. I want that too. Let me add what I know to what they've shared."
Offer a detailed alternative explanation: Research shows that corrections work significantly better when they explain why the misinformation seems credible rather than simply negating it. For cannabis, the claim patients have most likely encountered is that cannabis kills cancer cells — and this is built on real research. Cannabinoids do show antiproliferative effects in cell-line studies. The correction isn't "that's false" but "here's what those studies actually show and why they don't yet translate to human treatment."
Help them evaluate future claims: Was this a study in humans or in cells? Peer-reviewed or social media? Does the source sell a cannabis product?
Plan to revisit: Corrected beliefs are fragile and vulnerable to re-exposure. Keep the door open: "Let's keep talking about this. I want you to have the best information as new studies come out, and I want to know what you're trying."
⚑ If on immunotherapy: Recruit their own motivation: "I hear that you want to do everything possible to fight this. I want that too. That's why I need to flag something specific — early data suggests THC may reduce the immune response your immunotherapy is designed to activate."
Scenario C: Communication Guidance
Your task
The patient has already changed or stopped treatment. Maintaining the therapeutic relationship is the clinical priority, because re-engagement with treatment, if it happens, will come through that relationship.
What to watch for
Research on psychological reactance shows that leading with clinical authority when a patient has already made an autonomous decision — expressing alarm, disappointment, or urgency — typically entrenches the position further rather than opening it to reconsideration. The more a patient feels pressured, the more committed they become to the decision they've made.
Opening the conversation
The misinformation has already produced a behavioral outcome — the patient has altered or abandoned treatment. Research suggests that beliefs become harder to revise when they are reinforced by identity, autonomy, and prior decisions. Start by understanding the patient's reasoning before attempting to change it.
When you discuss the evidence
The patient has most likely acted on the belief that cannabis can treat cancer itself. This belief is built on real research — cannabinoids do demonstrate antiproliferative effects in cell-line and animal model studies. The specific correction is the preclinical-to-clinical gap: a lot of things kill cancer cells in a lab that don't work inside a human body, and no completed clinical trial has shown that cannabis treats cancer in people. Correcting this now also means telling the patient that the basis for a major life decision was flawed. Engage the evidence only when the patient is open to it, and anchor it to their specific situation rather than correcting the general claim.
Key strategies
Explore ambivalence: Motivational interviewing theory holds that patients facing major health decisions often suppress one side of their ambivalence rather than resolving it. Questions that surface the suppressed side are more likely to produce movement than corrections: "What would change your mind?" or "What worries you most about your current plan?"
Be concrete and specific: Research on misinformation correction consistently shows that detailed, specific explanations are more effective than general warnings or simple negation. Be specific to their cancer, their stage, their prognosis: "For your specific diagnosis, the data on [treatment] shows [X outcome]. I want to make sure you have that number when you're weighing your options."
Address what's underneath: A patient who has left treatment has typically done so for reasons beyond the cannabis misinformation itself — fear of side effects, distrust of the medical system, alignment with a community that advocates alternatives, or experiences of being dismissed. If the underlying motivation is distrust, repeating clinical evidence will not work. If it's fear of side effects, discussing side effect management may matter more than discussing efficacy. The correction must engage the actual driver, not just the surface claim.
Respect autonomy without abandoning your clinical perspective: Respecting patient autonomy does not mean agreeing with the patient's decision — it means ensuring the decision is fully informed. You can be direct about the clinical stakes while respecting the patient's right to decide.
Schedule follow-up regardless of outcome: "Whatever you decide, I'd like to see you in [timeframe]. We can talk about how things are going." This communicates that the relationship is not contingent on treatment compliance. Research shows that sustained engagement — even without immediate behavior change — increases the probability of eventual change.
Involve the care team: If a patient has stopped curative-intent treatment, document the conversation and notify the broader care team. Consider whether social work, palliative care, patient navigation, or psycho-oncology should be involved — not to pressure the patient, but to ensure support is available.
⚑ If this patient was receiving or was planned for immunotherapy: If the patient is open to reconsidering treatment, the immunotherapy interaction becomes a concrete, specific piece of information — not "cannabis is bad for you" but "here is a specific way that cannabis may have reduced the effectiveness of this specific treatment." This specificity matters.